Canada - engelsk - Health Canada

gilead sciences canada inc - emtricitabine; tenofovir alafenamide (tenofovir alafenamide hemifumarate) - tablet - 200mg; 10mg - emtricitabine 200mg; tenofovir alafenamide (tenofovir alafenamide hemifumarate) 10mg - nucleoside and nucleotide reverse transcriptase inhibitors

Canada - engelsk - Health Canada

gilead sciences canada inc - emtricitabine; tenofovir alafenamide (tenofovir alafenamide hemifumarate) - tablet - 200mg; 25mg - emtricitabine 200mg; tenofovir alafenamide (tenofovir alafenamide hemifumarate) 25mg - nucleoside and nucleotide reverse transcriptase inhibitors

Storbritannien - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

gilead sciences international ltd - sofosbuvir - tablet - 400mg

Canada - engelsk - Health Canada

glaxosmithkline inc - belimumab - solution - 200mg - belimumab 200mg - immunosuppressive agents

Canada - engelsk - Health Canada

glaxosmithkline inc - belimumab - solution - 200mg - belimumab 200mg - immunosuppressive agents

USA - engelsk - NLM (National Library of Medicine)

seqirus pty ltd. - influenza a virus a/brisbane/02/2018 ivr-190 (h1n1) antigen (propiolactone inactivated) (unii: 0qk4u2v88l) (influenza a virus a/brisbane/02/2018 ivr-190 (h1n1) hemagglutinin antigen (propiolactone inactivated) - unii:re1mnp1ne6), influenza a virus a/kansas/14/2017 x-327 (h3n2) antigen (propiolactone inactivated) (unii: al8g7d406d) (influenza a virus a/kansas/14/2017 x-327 (h3n2) hemagglutinin antigen (propiolactone inactivated) - unii:mu3in5k1yc), influenza b virus b/maryland/15/2016 antigen (propiolacto - afluria® quadrivalent is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza a subtype viruses and type b viruses contained in the vaccine. afluria quadrivalent is approved for use in persons 6 months of age and older. afluria quadrivalent is contraindicated in individuals with known severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine including egg protein, or to a previous dose of any influenza vaccine (see description [11]) . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to afluria quadrivalent during pregnancy. women who are vaccinated with afluria quadrivalent during pregnancy are encouraged to enroll in the registry by calling 1-855-358-8966 or sending an email to seqirus at us.medicalinformation@seqirus.com. risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated ba

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

gilead sciences (nz) - bictegravir sodium 52.45mg equivalent to to 50 mg bictegravir;  ; emtricitabine 200mg;  ;  ;  ;  ; tenofovir alafenamide fumarate 28.04mg equivalent to to 25 mg tenofovir alafenamide;   - film coated tablet - active: bictegravir sodium 52.45mg equivalent to to 50 mg bictegravir   emtricitabine 200mg         tenofovir alafenamide fumarate 28.04mg equivalent to to 25 mg tenofovir alafenamide   excipient: croscarmellose sodium magnesium stearate microcrystalline cellulose opadry brown 85f165072 - biktarvy is indicated for the treatment of hiv-1 infection in adults and paediatric patients weighing at least 25 kg who are antiretroviral therapy (art)-na?ve or to replace the current antiretroviral regimen in those who are virologically-suppressed (hiv-1 rna < 50 copies/ml) on a stable antiretroviral regimen at the start of therapy with no history of treatment failure, and no known substitutions associated with resistance to the individual components of biktarvy.

Israel - engelsk - Ministry of Health

gilead sciences israel ltd - cobicistate; elvitegravir; emtricitabine; tenofovir alafenamide - film coated tablets - tenofovir alafenamide 10 mg; emtricitabine 200 mg; cobicistate 150 mg; elvitegravir 150 mg - emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat - gendevra is indicated for the treatment of human immunodeficiency virus 1 (hiv 1) infection without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir as follows:• in adults and adolescents aged from 12 years and with body weight at least 35 kg• in children aged from 6 years and with body weight at least 25 kg for whom alternative regimens are unsuitable due to toxicities.תוספת התוויה: 2/7/2019addition of new info to posology section: precaution in pregnant women

Israel - engelsk - Ministry of Health

gilead sciences israel ltd - emtricitabine; tenofovir alafenamide fumarate - film coated tablets - tenofovir alafenamide fumarate 10 mg; emtricitabine 200 mg - tenofovir disoproxil and emtricitabine - descovy is indicated in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type 1 (hiv 1).בקשה לשינוי התוויה: 14/8/19addition of new info to posology section: patients undergoing haemodialysis

Israel - engelsk - Ministry of Health

gilead sciences israel ltd - emtricitabine; tenofovir alafenamide fumarate - film coated tablets - tenofovir alafenamide fumarate 25 mg; emtricitabine 200 mg - tenofovir disoproxil and emtricitabine - descovy is indicated in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type 1 (hiv 1).בקשה לשינוי התוויה: 14/8/19addition of new info to posology section: patients undergoing haemodialysis